Remix Therapeutics™ Appoints Maria Koehler, M.D., Ph.D., as an Independent Board Director [Yahoo! Finance]
Repare Therapeutics Inc. - Common Shares (RPTX)
Company Research
Source: Yahoo! Finance
WATERTOWN, Mass. June 18, 2024 /PRNewswire/ -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers of disease, today announced the appointment of Maria Koehler , M.D., Ph.D., as an independent director to Remix's Board of Directors. "Dr. Koehler's industry knowledge and wealth of experience will prove invaluable as we advance our pipeline of RNA processing modulators, including our first-in-class lead program REM-422," said Peter Smith , Ph.D., Co-Founder and Chief Executive Officer of Remix. "We look forward to partnering with Dr. Koehler as Remix enters this exciting new era and continues progressing in the clinic." Dr. Koehler brings over 20 years of experience leading clinical and regulatory strategy operations for biotechnology and pharmaceutical companies focused on oncology research and development. She is currently the Chief Medical Officer of Repare Therapeutics,
Show less
Read more
Impact Snapshot
Event Time:
RPTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPTX alerts
High impacting Repare Therapeutics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
RPTX
News
- Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI [Yahoo! Finance]Yahoo! Finance
- Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRIBusiness Wire
- Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib [Yahoo! Finance]Yahoo! Finance
- Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial [Yahoo! Finance]Yahoo! Finance
- Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical TrialBusiness Wire
RPTX
Earnings
- 2/28/24 - Miss
RPTX
Sec Filings
- 6/20/24 - Form 4
- 6/20/24 - Form 4
- 6/20/24 - Form 4
- RPTX's page on the SEC website